Mass Tort Data Intelligence
Real-time docket tracking, filing velocity, and litigation intelligence across 50 active mass tort dockets.
Meta SJ Denied — 29-State AG Bellwether Locked In Aug 18 (MDL 3047)
Judge Yvonne Gonzalez Rogers (N.D. Cal.) denied Meta's summary judgment motion on June 30, teeing up a 29-state Attorney General bellwether trial for August 18, 2026 in the social media adolescent addiction MDL. The ruling rejects Meta's Section 230 and no-duty defenses at the summary-judgment stage — the same theories that failed in the March New Mexico state verdict now go to a federal jury with two-dozen-plus sovereign plaintiffs. Nearly 600 federal cases are consolidated in MDL 3047; the outcome cascades to Google, Snap, and Pinterest which are also defendants across the docket. Market reaction is already bifurcated: SNAP has bled -17.1% over the past 30 days on rolling regulatory pressure, while META round-tripped through the news with a competing AI-cloud rally on July 1. Investor read: differential legal risk is being priced into the smaller-cap defendants first.
Defendant Market Impact
Verdict Breakdown
MDL 3047 Concurrent Proceedings
Key Developments
SJ denied June 30 by Judge Gonzalez Rogers — Meta's escape routes closed
29-state Attorney General bellwether trial locked for August 18, 2026
~600 federal cases in MDL 3047 (N.D. Cal.) — nation's largest coordinated addiction docket
Section 230 defense rejected — same posture failed in March NM v. Meta ($2.1B verdict)
SNAP -17.1% 30-day vs META round-trip: smaller cap pricing legal risk first
Plaintiff Firm Rankings — Jul 10 – Jul 23, 2026
| # | Firm | City | Active Dockets | New | Leadership Status |
|---|---|---|---|---|---|
| 1 | Motley Rice LLC | Mt. Pleasant, SC | Social Media, AFFF, Talc | 45 | PSC — MDL 3047, MDL 2873 |
| 2 | Levin Papantonio Rafferty | Pensacola, FL | AFFF, Hair Relaxer, PowerPort | 38 | Co-Lead — MDL 2873 |
| 3 | Beasley Allen | Montgomery, AL | Paragard, Ozempic, Hair Relaxer | 32 | PSC — MDL 3094, MDL 2750 |
| 4 | Seeger Weiss LLP | New York, NY | Acetaminophen, FreeStyle Libre, Social Media | 30 | Co-Lead — MDL 3043 |
| 5 | Wisner Baum | Los Angeles, CA | Acetaminophen, Depo-Provera, Social Media | 28 | PSC — MDL 3043, MDL 3140 |
| 6 | Slater Slater Schulman | New York, NY | Uber, Lyft, Social Media | 25 | Lead — MDL 3084 |
| 7 | TorHoerman Law | Edwardsville, IL | Hair Relaxer, Paragard, Social Media | 22 | PSC — MDL 3060 |
| 8 | Weitz & Luxenberg | New York, NY | FreeStyle Libre, 1,4-Dioxane, Talc | 20 | PSC — MDL 2738 |
MDL Case Count Tracker — Jul 10 – Jul 23, 2026
50 dockets| Tort | MDL # | Total | New (Wk) | Trend | Key Development |
|---|---|---|---|---|---|
Tech | Pre-MDL | ~500+ | ~35 | FAST | State AG actions accelerating. Epic Games $520M FTC precedent. MDL formation expected 2026. |
Tech | 3047 | 10,000+ | ~30 | ACTIVE | Post-verdict momentum. Meta/Google appeal expected. Federal bellwether Jun 15 on track. |
Talc / J&JBorderline Consumer | 2738 | 67,200+ | ~45 | FILING | CA $950M verdict vacated Mar 17. Continued high-volume filing. |
Hair RelaxerOpen Consumer | 3060 | ~15,100 | ~25 | ACTIVE | BELLWETHER SELECTION: Judge Rowland selected 3 cases Apr 1. |
Chemical | 2873 | 15,250+ | ~40 | FILING | Steady high-volume intake. Motley Rice, Levin Papantonio active. |
Device | 2846 | 23,800+ | ~50 | FILING | Continued largest filing volume. |
Depo-ProveraOpen Pharma | 3140 | 3,490+ | ~40 | FAST | Expert deps completed Mar 20. Preemption motion under advisement. |
Pharma | 3092 | ~8,500 | ~5 | FLAT | Bellwether discovery continues. |
Ozempic / GLP-1Open Pharma | 3094 | 3,546+ | ~20 | ACTIVE | Entering critical Daubert/SJ phase. |
Bard PowerPortOpen Device | 3081 | 3,044+ | ~40 | ACTIVE | TRIAL IMMINENT: Cook bellwether Apr 21. |
Paragard IUDBorderline Device | 2750 | 3,600+ | ~25 | FILING | Beasley Allen, TorHoerman active. Mediation ongoing. |
Ozempic NAIONOpen Pharma | 3163 | 73+ | ~19 | FAST | Separate MDL created Dec 2025. NJ MCL active in parallel. |
Pharma | 3043 | ~3,025 | ~25 | FILING | Seeger Weiss, Wisner Baum active. |
Tech | 3171 | ~170 | ~20 | FAST | Rapid intake continues. |
Tech | 3084 | 2,075+ | ~15 | FILING | Slater Slater Schulman active. |
Cartiva SCIOpen Device | 3172 | ~400 | ~10 | FILING | Mediation ongoing. Bellwether May 26. |
Dupixent CTCLOpen Pharma | 3180 | 18+ | ~5 | FAST | JPML MDL motion filed. Ruling expected soon. |
Nitrous OxideOpen Consumer | Pre-MDL | ~325 | ~25 | FAST | Pre-MDL. Multiple firms active. |
FreeStyle LibreOpen Device | Pre-MDL | ~215 | ~15 | FILING | Seeger Weiss, Weitz & Luxenberg active. |
1,4-DioxaneOpen Chemical | E.D.N.Y | 30+ | ~3 | FILING | Weitz & Luxenberg, Napoli Shkolnik active. |
ByHeart FormulaOpen Consumer | Pre-MDL | ~22 | ~4 | FILING | JPML Birmingham hearing Mar 26. Ruling imminent. |
Chemical | 2741 | 4,200+ | ~15 | ACTIVE | Bayer settlement ongoing. New cases still filing. |
Chemical | E.D.N.C. | 95,000+ | ~200 | FILING | PACT Act claims. Federal government defendant. |
Zantac / RanitidineClosed Pharma | 2924 | 2,100+ | ~2 | FLAT | Most claims dismissed. Science rulings unfavorable. |
ParaquatOpen Chemical | 3004 | 5,400+ | ~35 | FILING | Parkinson's disease link. Syngenta/Chevron defendants. |
Consumer | Pre-MDL | ~500 | ~20 | FAST | Emerging ovarian cancer claims separate from J&J. |
NEC Baby FormulaOpen Consumer | 3026 | 1,800+ | ~12 | ACTIVE | Abbott/Mead Johnson. Premature infant NEC claims. |
Pharma | 3043 | ~3,025 | ~25 | FILING | Autism/ADHD link. Retailers as defendants. |
TepezzaOpen Pharma | Pre-MDL | ~200 | ~10 | FAST | Hearing loss side effect. Horizon Therapeutics. |
Philips CPAPOpen Device | 3014 | 750+ | ~8 | ACTIVE | Foam degradation. Cancer risk claims. |
ElmironBorderline Pharma | 2973 | 1,200+ | ~3 | FLAT | Vision damage. Settlement discussions ongoing. |
Exactech ImplantOpen Device | 3044 | 900+ | ~10 | FILING | Polyethylene insert failures. |
BelviqOpen Pharma | Pre-MDL | ~150 | ~8 | FAST | Cancer risk. Pulled from market 2020. |
Chemical | Pre-MDL | ~400 | ~15 | FAST | PFAS exposure. Emerging litigation. |
Toxic Baby FoodOpen Consumer | Pre-MDL | ~300 | ~10 | FILING | Heavy metals in baby food. Multiple defendants. |
FluoroquinoloneBorderline Pharma | Pre-MDL | ~250 | ~2 | FLAT | Cipro/Levaquin. Peripheral neuropathy. |
Proton Pump InhibitorsClosed Pharma | 2789 | 12,000+ | ~5 | FLAT | Nexium/Prilosec. Kidney damage. Mostly settled. |
IVC FilterClosed Device | 2641 | 3,800+ | ~3 | FLAT | Bard/Cook. Filter migration/fracture. |
RisperdalClosed Pharma | 2767 | 900+ | ~2 | FLAT | Gynecomastia. Most cases resolved. |
3M EarplugsClosed Device | 2885 | Settled | 0 | FLAT | $6B settlement complete. Monitoring ongoing. |
ValsartanClosed Pharma | 2875 | 1,400+ | ~3 | FLAT | NDMA contamination. Cancer claims. |
Consumer | 3038 | 4,500+ | ~15 | ACTIVE | Youth vaping. School district claims. |
Other | Pre-MDL | ~50 | ~3 | FAST | Antitrust. PGA merger implications. |
Tech | Pre-MDL | ~100 | ~5 | FILING | Driver-on-passenger assault claims. |
WeChat PrivacyOpen Tech | Pre-MDL | ~75 | ~4 | FAST | Data privacy violations. CCPA claims. |
Monsanto PCBOpen Chemical | 2342 | 2,500+ | ~10 | FILING | Environmental contamination. School claims. |
Consumer | 2738 | Part of Talc | ~20 | FILING | Subset of Talc MDL. |
Pharma | Pre-MDL | ~100 | ~5 | FAST | Autoimmune injury claims. Merck defendant. |
Metal-on-Metal HipClosed Device | 2244 | 4,000+ | ~2 | FLAT | DePuy/Stryker. Mostly resolved. |
Pharma | Pre-MDL | ~50 | ~3 | FAST | Immune-related organ failure. Merck defendant. |
Critical Dates — Next 60 Days
11 events| Date | Docket | Event | Investor Significance |
|---|---|---|---|
| Apr 1 | Hair Relaxer MDL 3060 | Bellwether case selection by Judge Rowland | Sets timeline for first federal trial; key valuation signal |
| Apr 7 | Social Media MDL 3047 | Expert report deadline — algorithmic amplification | Core liability theory; affects Daubert outcomes |
| Apr 10 | Social Media (NM State) | Google appeal filing deadline | Appellate strategy signals settlement posture |
| Apr 14 | Social Media JCCP 5255 | CA state coordination hearing | State-level consolidation affects case volume projections |
| Apr 14 | Social Media (NM State) | Post-trial motions deadline | JNOV ruling could modify $2.1B verdict |
| Apr 21 | Bard PowerPort MDL 3081 | Cook Medical bellwether trial begins | First trial in catheter port docket; high settlement leverage |
| May 5 | Depo-Provera MDL 3140 | Preemption motion ruling expected | Threshold legal issue — dismissal risk if granted |
| May 12 | Ozempic MDL 3094 | Daubert hearing — general causation experts | Make-or-break for GLP-1 litigation viability |
| May 26 | Cartiva SCI MDL 3172 | First bellwether trial | Initial trial outcome sets negotiation baseline |
| Jun 2 | Talc MDL 2738 | J&J 3rd prepackaged bankruptcy hearing | Could resolve or further delay 67K+ claims |
| Jun 15 | Social Media MDL 3047 | Federal bellwether trial begins | Landmark federal trial; massive settlement implications |
New Filings — Jul 10 – Jul 23, 2026
| Case | Defendant | Court | Theory | Lead Firm |
|---|---|---|---|---|
| Rodriguez v. Meta Platforms | Meta Platforms, Inc. | N.D. Cal. | Product liability — algorithmic addiction | Motley Rice LLC |
| Thompson v. Bard Medical | Bard Medical / BD | D. Ariz. | Device failure — catheter fracture | Levin Papantonio |
| Williams v. Pfizer Inc. | Pfizer Inc. | S.D.N.Y. | Failure to warn — Depo-Provera meningioma | Wisner Baum |
| Garcia v. Novo Nordisk | Novo Nordisk A/S | E.D. Pa. | GLP-1 gastroparesis / bowel obstruction | Beasley Allen |
| Davis v. Lyft, Inc. | Lyft, Inc. | N.D. Cal. | Negligent hiring — sexual assault | Slater Slater Schulman |
| Chen v. Abbott Labs | Abbott Laboratories | N.D. Ill. | Device defect — FreeStyle Libre burns | Seeger Weiss LLP |
Analyst Notes & Portfolio Strategy
Priority assessments, stage analysis, and portfolio positioning across active mass tort dockets.
Analyst Notes — Investor Outlook
Social Media Youth Addiction
Elevated PriorityThe NM verdict fundamentally shifts the litigation landscape. Federal bellwether on June 15 is the next major catalyst. Expect heightened settlement pressure on Meta/Google. Monitor appellate timeline closely — a sustained verdict dramatically increases portfolio exposure.
Talc / J&J
Bankruptcy WatchThird prepackaged bankruptcy attempt (June 2 hearing) remains the central variable. CA verdict vacation adds complexity. Resolution of 67K+ claims hinges on bankruptcy court approval of $8.9B trust proposal.
Hair Relaxer
Trial PreparationBellwether selections signal active progression. Three cases chosen April 1 will define trial strategy. L'Oreal, Revlon exposure significant. Watch for Daubert rulings on causation experts in coming weeks.
Depo-Provera
Elevated PriorityPreemption ruling (expected May 5) is threshold issue. If denied, rapid case growth likely accelerates. Pfizer exposure could be substantial given long market history and meningioma causation evidence.
Ozempic / GLP-1
Critical JunctureMay 12 Daubert hearing is make-or-break. Favorable ruling opens massive liability exposure for Novo Nordisk and Eli Lilly. Unfavorable ruling could significantly deflate docket. High-stakes binary outcome.
Bard PowerPort
Trial ImminentCook Medical bellwether (April 21) is the first catheter port trial. Outcome will set settlement benchmarks. BD/Bard cases to follow. Device failure evidence is strong — favorable plaintiff verdict expected.
Opportunities by Stage
Early signals. Pre-MDL formation. First-mover window.
Active investigation. Firms building inventory.
Meaningful case volume. Bellwethers approaching.
Multi-front mass tort. Settlement pressure.
The Diversified Core Portfolio
8 curated mass tort positions across 5 sectors and 4 stages.
Don't miss a ruling, verdict, or filing.
Every Monday: critical docket developments, filing velocity changes, bellwether outcomes, and portfolio signals — in one email.
Upload expert documents into the live docket board
Upload litigation reports, filings, or normalized JSON. Trusted docket facts become homepage overrides when they match a live MDL or tracked docket.